Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation

J Comput Aided Mol Des. 2019 May;33(5):521-530. doi: 10.1007/s10822-019-00202-2. Epub 2019 Apr 15.

Abstract

Although the mechanism of Alzheimer's disease (AD) is still not fully understood, the development of multifunctional AChE inhibitors remains a research focus for AD treatment. In this study, 48 AChE candidate inhibitors were picked out from SPECS database through a pharmacophore- and molecular docking-based virtual screening. The biological evaluation results indicated that four compounds 7, 29, 41 and 48 with different scaffolds exhibited potent and selective AChE inhibitory activity, with the best IC50 value of 1.62 ± 0.11 μM obtained for 48. Then their mechanism of action, the inhibition on Aβ aggregation, neurotoxicity, and neuroprotective activity against Aβ-induced nerve cell injury were well studied. The binding mode of 48 with AChE was also proposed. The present bioassay results indicated that these multifunctional AChE inhibitors were worth for further structural derivatization to make them the anti-AD lead compounds.

Keywords: AChE inhibitor; Anti-Aβ aggregation; Molecular docking; Neuroprotective activity; Pharmacophore model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholinesterase / chemistry
  • Acetylcholinesterase / metabolism*
  • Alzheimer Disease / drug therapy
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Cell Line
  • Cholinesterase Inhibitors / chemistry*
  • Cholinesterase Inhibitors / pharmacology*
  • Drug Design
  • Electrophorus
  • Humans
  • Molecular Docking Simulation
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology
  • Protein Aggregates / drug effects

Substances

  • Amyloid beta-Peptides
  • Cholinesterase Inhibitors
  • Neuroprotective Agents
  • Protein Aggregates
  • Acetylcholinesterase